Get the Stockscreener App
3.93
0.88%
-0.03
Recursion Pharmaceuticals Inc stock is traded at $3.93, with a volume of 17.35M.
It is down -0.88% in the last 24 hours and up +18.40% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.96
Open:
$3.95
24h Volume:
17.35M
Relative Volume:
1.01
Market Cap:
$2.08B
Revenue:
$66.41M
Net Income/Loss:
$-559.78M
P/E Ratio:
-3.269
EPS:
-1.2022
Net Cash Flow:
$-328.09M
1W Performance:
+6.95%
1M Performance:
+18.40%
6M Performance:
-19.24%
1Y Performance:
-20.39%
1-Day Range:
$3.81
$4.05
1-Week Range:
$3.61
$4.09
52-Week Range:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.925 | 2.02B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
524.81 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.55 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
920.71 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
192.06 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Recursion Pharmaceuticals (NASDAQ:RXRX) stock gains as short interest and Russell flows hit AI-biotech rally - TechStock²
Form 144 RECURSION PHARMACEUTICALS For: 6 July By Investing.com - Investing.com Canada
Insider sells 340,440 RXRX shares (NASDAQ: RXRX) - Stock Titan
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed? - Yahoo Finance UK
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) beats out biotech funds as filings, spending become focus - TechStock²
Recursion Pharmaceuticals Stock (RXRX) Opinions on Technical Consolidation - Quiver Quantitative
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock - Investing.com
Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock By Investing.com - Investing.com UK
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Globe and Mail
RXRX rallies past biotech ETFs as short interest, insider-sale filings shape coming week - TechStock²
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain - Moomoo
RXRXRecursion Pharmaceuticals Inc Volatility & Greeks - Finviz
Recursion Pharmaceuticals (NASDAQ:RXRX) pops, short interest still much bigger than new founder-sale alert - TechStock²
Form 4 Recursion Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares - Stock Titan
Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant - Stock Titan
RXRX Stock Draws ARK Buying As AI Drug Story Builds - timothysykes.com
Christopher C. Gibson lists multiple Class A sales (RXRX) - Stock Titan
Form 144 RECURSION PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
RXRX (NASDAQ: RXRX) insider sale notice — 100,000 Class A shares - Stock Titan
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Anthropic Launches Claude Science to Enter Life Sciences, AI Drug Discovery Stocks Tumble in Response - NAI500
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Does Recursion (RXRX) Russell Value Index Lift Recast Its AI Biotech Story as Deep Value? - simplywall.st
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 2000 Value Benchmark - marketscreener.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on ARK Invest's Recent Share Purchase - Moomoo
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000E Value Benchmark - marketscreener.com
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals (RXRX) ascends while market falls: Some facts to note - MSN
RXRX Stock Gains Attention As ARK Investment Steps In - timothysykes.com
Recursion Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:RXRX) - TradingView
Recursion Pharmaceuticals Stock Short Interest Rises to 36.75% - Quiver Quantitative
8RL Forecast — Price Target — Prediction for 2027 - TradingView
Cathie Wood's investment moves on June 25! Added over 890,000 shares of Recursion Pharmaceuticals in a major purchase, while selling more than 170,000 shares of Alibaba - Moomoo
Did Recursion Pharmaceuticals' Q4 Beat Signal a Turning Point - Kavout | AI
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying - The Globe and Mail
Enterprise value to EBIT forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals (RXRX) Short Interest & Short Float | Updated Jun 2026 $RXRX - MarketBeat
Why Could (NASDAQ:RXRX) Stay on Nasdaq Composite Radar? - Kalkine Media
Recursion Pharmaceuticals (RXRX) Sees Bulk Purchase from ARK Inv - GuruFocus
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Q4 2025 earnings summary - Quartr
1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company - Yahoo Finance
Recursion Pharmaceuticals Inc (RXRX) Institutional Confidence - TradingKey
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Sun Elaine D - Moomoo
Form 4 Recursion Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Australia
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.26%
2.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):